Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Liabilities and Shareholders Equity (2023 - 2026)

Contineum Therapeutics' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $261.3 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 31.82% to $261.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $911.7 million through Mar 2026, up 7.45% year-over-year, with the annual reading at $276.6 million for FY2025, 29.97% up from the prior year.
  • Liabilities and Shareholders Equity came in at $261.3 million for Q1 2026, down from $276.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $276.6 million in Q4 2025 to a low of $123.6 million in Q1 2024.
  • The 4-year median for Liabilities and Shareholders Equity is $205.6 million (2024), against an average of $201.4 million.
  • Year-over-year, Liabilities and Shareholders Equity surged 63.24% in 2024 and then fell 17.38% in 2025.
  • Contineum Therapeutics' Liabilities and Shareholders Equity stood at $130.4 million in 2023, then surged by 63.24% to $212.8 million in 2024, then grew by 29.97% to $276.6 million in 2025, then fell by 5.53% to $261.3 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Liabilities and Shareholders Equity are $261.3 million (Q1 2026), $276.6 million (Q4 2025), and $190.8 million (Q3 2025).